Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
8-10-2017 12:00 AM

Design and Synthesis of Hyaluronan:RHAMM Interaction
Inhibitors
Emily Rodrigues, The University of Western Ontario
Supervisor: Dr. Len Luyt, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Chemistry
© Emily Rodrigues 2017

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Organic Chemistry Commons

Recommended Citation
Rodrigues, Emily, "Design and Synthesis of Hyaluronan:RHAMM Interaction Inhibitors" (2017). Electronic
Thesis and Dissertation Repository. 4876.
https://ir.lib.uwo.ca/etd/4876

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

ii

Abstract
A major component of the extracellular matrix is hyaluronan, a regulator cell
migration/survival and differentiation during response-to-injury processes. The receptor for
hyaluronan-mediated motility (RHAMM) binds to HA and has limited constitutive
expression but is upregulated during tissue injury. Blocking HA fragment:RHAMM
interactions has therapeutic potential for treating cancer but truncation of RHAMM into
peptides mimicking only the HA binding domains is predicted to lose their natural α-helical
structure. The goal of this project is to explore the effects cyclizing each binding domain has
on helicity and its biological effect. Eighteen peptides were synthesized and cyclized using
lactam bridges. The peptides were analyzed by circular dichroism spectroscopy and one
stapled peptide exhibited a 4-fold increase in helicity compared to the unstapled sequence
and significantly decreased migration, inflammation, and fibrosis in vitro. This cyclic peptide
is a novel protein-carbohydrate inhibitor and has the potential to be a therapeutic in the
cancer treatment.

Keywords
Peptide, cyclization, lactam, alpha helix, receptor for hyaluronan mediated motility,
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Chapter 1

1

Introduction

1.1 Hyaluronan
The extracellular matrix (ECM) is a tissue component that provides structural and
biochemical support to neighboring cells and that is constantly undergoing modifications to
better suit the needs yof those cells. These changes are not always benign: during cancer
metastasis, the regular ECM framework is disrupted and manipulated to facilitate tumor
initiation and progression1,2. A major component of the ECM is hyaluronan (HA), a
glycosaminoglycan (GAG) that contains repeating disaccharide units of N-acetyl-Dglucosamine and D-glucuronic acid (Figure 1.1).

Figure 1.1 - Structure of hyaluronan.

HA has a variety of functions which include the regulation of proliferation, cell
motility, and adhesion, all of which are factors in cancer metastasis3–6. It is important to note
that the functions of HA are highly size-dependent. Native high molecular weight (MW) HA
(>500 kDa) has the ability to reduce inflammation. In the case of tissue injury, HA can be
fragmented by reactive oxygen and nitrogen species (ROS and RNS, respectively) such as
hydroxyl radicals, peroxynitrite, or peroxynitrous acid7. HA can also be cleaved by
hyaluronidases (Hyals), a family of proteins that are able to cleave the β-1,4-glycosidic bond
of HA8. When HA fragments, the resulting lower MW HA (e.g. <200 kDa) aids in the
promotion of inflammation and migration of cells (Figure 1.2).
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Figure 1.2 - HA can be fragmented by hyaluronidases (Hyals) or reactive oxygen species
(ROS) in a tumor. When HA is fragmented, various cellular functions can occur due to
interactions with the RHAMM/CD44 complex.

1.2 Receptor for Hyaluronan Mediated Motility (RHAMM)
Like many receptor ligands, HA is known to activate certain receptors, one of which
is the receptor for hyaluronan mediated motility (RHAMM). RHAMM can be located on the
cell surface as a glycosylphosphatidylinositol (GPI) linked protein, or it can be found
internally within the cytoplasm9. On the cell surface, RHAMM is able to interact with other
cell-surface receptors, such as CD44; this interaction is believed to activate the ERK1/2 MAP
kinase pathway10,11. When RHAMM is located intracellularly, it acts as a mitotic
spindle/centrosomal protein and can affect mitotic spindle integrity11,12. RHAMM mRNA
expression in adult homeostatic tissue is tightly regulated; expression typically remains very
low, but it transiently increases when tissue injury occurs11. When there are increased levels
of RHAMM expression found in tumors, it is correlated with higher mortality rates

13

. For

this reason, blocking the HA fragment:RHAMM interaction has therapeutic potential, as it
could interrupt a vital facilitator of metastasis. In prostate cancer (PCa) specifically, elevated
levels of RHAMM have been observed, as well as aberrant HA:RHAMM signaling in a
metastatic cells line, PC3MLN414,15.
RHAMM is a 72 kDa protein that has been shown to be mainly α-helical by 2D
nuclear magnetic resonance (NMR)5. Yang et al. observed that there are two HA binding
domains (HABD) in RHAMM, located near the C-terminus of the protein, that are 10 and 11
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amino acids in length respectively; these domains are separated by a 15 amino acid leucine
zipper (Figure 1.3)6.

Figure 1.3 - Sequence of the C-terminal RHAMM(518-576) (top line) showing the two
binding domains (underlined) and the secondary structure prediction by 2D NMR
(bottom line). Depiction of the truncation of the sequence shows that it is possible to
obtain a low molecular weight peptide with an α-helical characteristic. H = α-Helix; C
= Random coil; E = Extended Coil

The HABDs are within two α-helical portions of RHAMM and have a BX7B binding
motif, where B is a basic residue (such as lysine or arginine) and X is any non-acidic residue
(these are generally hydrophobic)5,6. The RHAMM HABDs have a positively charged surface
due to the abundance of lysine and arginine residues that orient themselves such that they are
exposed to solvent when in an α-helical confirmation. The positively charged surface binds
through ionic interactions with the negatively charged carboxylate ions present in HA5. The
regions surrounding the HABDs of RHAMM are thought to extend inward to form a
hydrophobic core, which assists in stabilizing the secondary structure5; as such, this can
contribute to the loss of secondary structure that occurs when the amino acid sequence is
truncated to include just one of binding domains.

1.3 Peptides as Drugs
Proteins are stabilized by their natural biological environment and by binding to their
endogenous target via one or more small regions in the amino acid sequence of the protein16.
The biological activity of proteins is dependent on their three-dimensional structure,
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including secondary structure, which is in turn governed by their amino acid sequence16. The
secondary structure of a protein helps align the binding region properly for recognition of a
specific ligand.
In drug design, the focus of pharmaceutical development is typically on either small
molecules (compounds with a molecular weight less than 500 Da) or on large biologics
(compounds with a molecular weight greater than 5000 Da)17. With these two classes taking
the low and high molecular ranges, peptides fit nicely in between as they typically contain
less than 50 amino acids and have molecular weights that fall between these two classes of
drugs17. They are smaller than their larger protein biologic counterparts, meaning that they
are often less expensive and easier to manufacture than biologics while still maintaining
similar specificity and potency towards their intended target17. However, shortened unbound
peptides have a propensity to lose their secondary structure under physiological conditions,
mostly due to loss of side-chain interactions such as hydrogen bonding or electrostatic forces.
These side-chain interactions facilitate the formation of the secondary structure needed for
optimal binding18,19, as greater affinity is observed when the ligand and receptor are both in
their native conformation 16.
There are three main divisions of protein secondary structure: random coil, β-sheet,
and α-helix that have been shown to be important for protein-peptide interactions. About 62
percent of protein-protein complexes in the Protein Data Bank include an α-helix interaction;
this indicates that helical structures play a major role in mediating many biological processes,
including those that involve therapeutic targets16,19. The helix-coil transition theory states that
there is a high energy requirement needed for organizing three consecutive amino acids in a
helical conformation, limiting the formation of helices and potentially the activity of
shortened peptides20. This energy barrier is thought to be overcome by pre-folding shortened
peptides, and would therefore enable truncated peptides to adopt the desired α-helix
conformation21.

1.4 Synthetic Stapling Methods
One additional disadvantage of peptides as therapeutics, is that peptides suffer from
protease hydrolysis in vivo, and therefore have limited biological stability16. To overcome
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this problem, strategies such as capping, amidation, and the addition of unnatural amino acids
have been used. Another approach is the cyclization of peptides, which results in a
constrained structure with limited flexibility and less rotatable bonds. Cyclization increases a
peptide’s resistance to protease degradation in vivo, as the α-helix diameter of the cyclized
peptide is too large to fit into protease active sites16. Moreover, membrane permeability
improves when a molecule has a less polar surface and fewer rotatable bonds. Therefore,
cyclic peptides may have an improved ability to move across the epithelial barrier of the
gastrointestinal tract, indicating greater potential for oral bioavailability compared to their
noncyclic counterparts17. Peptide cyclization is a method of pre-folding shortened peptides,
as it promotes α-helix formation prior to target binding, and may therefore increase the
biological activity of these shortened peptides19. Synthesis of cyclic helical peptides does
require that the sequence has the natural propensity to fold into an α-helix; without this,
cyclization may not force the peptide into the desired conformation18.
Cyclization can be introduced to a peptide by modifying the side chains of its amino
acid residues. α-helical peptides have 3.6 amino acids per turn, which results in residues at
positions i, i+4, and i+7 occurring on the same face of the helix when the peptide is folded
correctly19. It is ideal to join i, i+4/i+7 residues by synthetically introducing covalent bonds,
referred to as ‘staples’, to stabilize the α-helical conformation22. To identify the optimal
location for a staple, a form of structure-activity relationship study termed a ‘staple scan’ is
performed. This is achieved by introducing a covalent bond between every i and i+4 pair of
residues that are not essential for target binding and subsequently evaluating the structure for
helicity and biological acitivty18.
Currently there are four prevalent stapling techniques capable of promoting a helical
structure are reported in the literature: a lactam bridge between side chains, a hydrocarbon
linker between side chains, a metal-ion clip, or a hydrogen bond surrogate ( Figure 1.4)17,19.
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Figure 1.4 - The four methods of constraining a peptide into an α-helix: (a) lactam
bridge; (b) hydrocarbon staple; (c) metal-ion clip; (d) hydrogen bond surrogate.

Different stapling strategies have different propensities to induce α-helical effects, as
some staples produce peptides are optimally helical in water, while others may require
secondary structure stabilizing solvents, such as trifluoroethanol (TFE), to increase the
helicity of the peptide for analysis16. Hydrocarbon and lactam bridges tend to be more
flexible, though this depends on the lengths of the side chain linkers18. Shorter staples have
been hypothesized to create more rigid and stable helices22, but ring size in cyclized peptides
is also dependent on the sequence and confirmation23. In all cases, the linker chain for
cyclization should be large enough to overcome ring strain, which in turn will prevent the
need for a high activation energy to complete the cyclization23. When designing a cyclic
peptide, it is imperative to remember that the side chains that are modified to create these
linkers can no longer be involved in target recognition, so selection of position and amino
acids to be replaced must be carefully considered. Cyclization steps are typically carried out
on-resin as opposed to in-solution; this is due to the increased possibility of polymerization
or dimerization during in-solution cyclization, as well as time-consuming dilution and
purification leading to lower yields24. As these peptides are ultimately being designed as
therapeutics, we decided to focus on lactam bridge cyclization due to its ease of synthesis and
increased stability in vivo compared to the other techniques discussed.
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1.5 Analysis of α-Helicity
Circular dichroism (CD) spectroscopy is a technique used to analyze the secondary
structure of peptides and proteins. The optical technique of CD analyzes the extent to which
exposed asymmetric molecules can absorb right and left handed circularly polarized light25.
The chromophores of the amides in the peptide’s primary amino acid sequence causes
different excitation interactions that produce different features on the spectra depending on
the amides’ positioning (Figure 1.5a)26. Due to the differences in secondary structure, it has
been observed that the CD spectrum for an α-helix is unique compared to those of other
secondary structures. For a protein with an α-helix, two negative bands are observed at
222nm and 208nm and one positive band is observed at 193nm, while linear disordered
proteins show one negative band around 195nm and shallow maxima at 210nm25. However,
when comparing α-helical proteins and peptides to linear sequences, it is important to
consider that macromolecules are able to adopt varying degrees of each conformation,
depending on the environment surrounding each section. This will change the appearance of
the CD spectrum, as the absorbance will be a mixture of the conformations present in the
peptide or protein (Figure 1.5b)26.
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Figure 1.5 - (a) Experimental circular dichroism spectra of poly-L-lysine in the αhelical, β, and random conformation; (b) Calculated circular dichroism of poly-L-lysine
containing 0% β and varying percentages of α-helix and random coil26.

As this project deals with stapling a small region out of the whole sequence, it is
assumed that the conformation of the entire peptide will not be 100 percent helical, as the
termini of the peptide will have decreased stabilizing support. This may result in a
combination of a random coil and α-helix, depending on how well the staple is able to induce
helicity in areas of the peptide not contained within the cyclic region.

1.6 Surface Plasmon Resonance (SPR)
To be able to test the ability of synthesized peptides to bind to their natural ligand (i.e.
HA), surface plasmon resonance (SPR) will be used. The technique of SPR has been used
and continuously improved since its inception in 197727. There have been many refinements
to the base technology over the years, but its appeal – the ability to test the binding of
unmodified compounds to a target bound to a surface (e.g. a chip) – has always remained the
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same. SPR works upon the basis of measuring the mass change of a surface in real time. This
mass change can contain kinetic and equilibrium (steady state) information28. The surface of
the SPR chip can be composed of a variety of different metals, but gold is typically used as it
is chemically inert and highly stable28. This gold surface can be readily modified with a
ligand, and then an unmodified analyte can be released onto the surface (Figure 1.6).

Figure 1.6 - How the binding of an analyte to a bound ligand is able to be measured
using SPR.

In this thesis, a localized surface plasmon resonance (LSPR) was used instead of
traditional SPR. LSPR differs from SPR by using gold nanoparticles instead of the
continuous film that is traditionally used in SPR. To calculate analyte binding, LSPR
measures the small change in the absorption of light of the nanoparticles, as opposed to the
conventional measurement of change in reflected angle of light. Absorbance can be used in
LSPR as nanoparticles produce a strong absorbance peak in the visible light range; a shift in
this peak reflects the change in the refractive index of the nanoparticles when a binding event
occurs (Figure 1.7).

10

Figure 1.7 - The difference in how kinetic information is obtained in (a) traditional SPR
and (b) localized SPR.

1.7 Objectives of Thesis
The purpose of this thesis is to create a potential peptide therapeutic that is able to
prevent the RHAMM:HA fragment interaction from occurring. This will be done by
synthesizing both HABDs and performing an i, i+4 lactam staple scan to identify the optimal
staple position. These peptides will be analyzed by CD spectroscopy to quantify the degree
of α-helicity, and by SPR to determine binding to HA. It is hypothesized that the formation
of a lactam bridge will increase both the helicity of the peptide and its binding towards HA.
The cyclized peptide that shows the best α-helical conformation will become the lead
compound for an alanine scan in order to identify the most essential residues for binding.
This lead cyclized peptide candidate will then undergo in vitro assays to assess its ability to
inhibit migration of cells and the release of inflammatory markers. This will indicate its
potential for disrupting the RHAMM:HA fragment interaction that allows cancer cells to
display increased migration and proliferation.
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Chapter 2

2

Design, synthesis, and evaluation of stapled peptides that

mimic the hyaluronan binding domains of RHAMM
2.1 Introduction
Cancer is a growing concern worldwide, as mortality rates from cancer have the
potential to surpass those of heart disease1. Metastatic tumors are especially problematic, as it
is the metastases forming distant from the primary tumor site that are the main cause of death
in patients2. In order for metastases to form, the extracellular matrix (ECM) must be modified
to make the cancer cell movement favorable3. The ECM provides structural and biochemical
support for its surrounding cells and contains many chemoattractants, thereby allowing it to
regulate the migration of cells3. A main component of the ECM is hyaluronan (HA), a
glycosaminoglycan consisting of repeating disaccharides units of N-acetyl-D-glucosamine
and D-glucuronic acid3,4. HA has a variety of functions that have been shown to regulate
proliferation, cell motility, and adhesion, all of which are important in cancer metastasis5–8.
HA function depends on the carbohydrate’s ability to activate certain receptors, such as the
receptor for hyaluronan mediated motility (RHAMM).
RHAMM can be located on the cell surface as a glycosylphosphatidylinositol (GPI)
linked protein, or it can be found intracellularly within the cytoplasm. On the cell surface,
RHAMM is interacts with other cell-surface receptors, such as CD44, which is believed to
activate the extracellular signal-regulated kinase (ERK1/2)/mitogen activated protein kinase
(MAPK) pathway9,10. RHAMM expression is tightly regulated: typically, it remains very low
in adult homeostatic tissue, but mRNA expression increases due to tissue injury10. Increased
RHAMM expression found in tumors have a positive correlation with a poor outcome for the
patient11. Due to this, blocking the HA fragment:RHAMM interaction could interrupt the
vital role in metastasis, leading to a potential therapeutic.
RHAMM is a 72kDa protein that is mainly α-helical as determined by 2D NMR7. It
has two HA binding domains (HABD) which are located towards the C-terminus region of
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the protein within two α-helical regions that are 10 and 11 amino acids in length7,12,13. Using
site-directed mutagenesis, Yang et al. discovered that RHAMM and other HA-binding
proteins have a characteristic BX7B motif, where B is a basic residue (such as lysine or
arginine) and X is any non-acidic residue that is generally hydrophobic5. It was observed that
in the first HABD, four Lys residues (K401, K411, K405, and K409) were found to be
important for interaction with HA5. Mutation of the residues K430, R431, or K432 within the
second binding domain saw a decrease in HA binding. Also within the second HABD, when
K423 was changed to Asn, there was no interaction with HA observed, indicating that there is
a need for proper spacing of the basic amino acids for binding to HA5. It is the positive
charges on these basic residues that are able to interact with the negatively charged
carboxylic acid on HA. This clustering of amino acid charges flanking non-acidic residues
was observed when the peptide RG3RG2R2 was shown to have similar binding to HA as the
second HABD5. The regions that surround the HABDs of RHAMM are thought to extend
inwards to form a hydrophobic core, which assists in stabilizing the secondary structure,
allowing the basic residues to be properly aligned to bind to HA7. If these surrounding
regions are lost, it could be a contributing factor to the loss of secondary structure when the
amino acid sequence is truncated to include just one of the binding domains.
The identification of protein-carbohydrate inhibitors (PCI) has largely focused on
identifying moieties that mimic the carbohydrate function. However, creating this type of PCI
poses a difficulty, as designing a carbohydrate mimic containing the specific multivalences
required to increase binding strength between two biological targets can be challenging14.
However, the focus can be switched to the protein component of the PCI. In order to create a
drug-like molecule, peptides can be used instead of their larger protein counterparts, as it
makes them less expensive and often easier to manufacture while still having good
specificity and potency to their endogenous ligand15. Previously, RHAMM mimicking
peptides have been developed through the use of phage display libraries4,16. One peptide,
peptide 15-1, was found to have a 40 percent homology with the linker region between the
two HABDs of RHAMM and was able to decrease fibroblast migration and reduce
inflammation and fibrosis4. Additionally, peptides have been developed that contain the Mus
musculus sequence of the linker region between the two HABDs of RHAMM, and have been
shown to increase adipogensis in mammary fat pads of mice17. However, a disadvantage of
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peptides deriving from a protein sequence is that they are unlikely to retain their secondary
structure under physiological conditions due to the absence of stabilizing residues that enable
the protein to properly fold15,18. A lack of secondary structure in a recognition site-mimicking
peptide increases the energy necessary for target binding, as the specific conformation must
form upon binding. Due to this, promoting secondary structure formation (such as an αhelix) in these short peptides prior to binding, may overcome the energetic penalty and
potentially increase biological activity19.
One technique that can achieve this goal is the cyclization of peptides, which can
induce helical formation within the cyclic portion. Cyclizing peptides results in a structure
with limited flexibility and increased resistance to protease degradation, which can correlate
to improved stability in vivo as the diameter of the α-helical cyclized peptide is larger than
the protease active sites18. To aid in the synthesis of cyclic peptides, it is desirable for the
linear peptide chain to have the propensity to fold into an α-helix. In order to identify the
optimal location within a sequence for the cyclic region to promote helical formation while
maintaining binding affinity to a specific target, a ‘staple scan’ can be performed. This is
done by manipulating each residue that is not essential for target binding, and subsequently
evaluating the ensuing structure20. In an α-helix, which contains 3.6 amino acid residues per
turn, residues at positions i, i+4, and i+7 occur on the same face of the helix when the
peptide is folded correctly19; therefore, introducing covalent bonds via stapling at these
positions can stabilize an α-helical conformation21.
To investigate the effect that truncation has on the bioactivity and helicity of the
RHAMM HABDs and the subsequent cyclization, a staple scan was performed for both the
first HABD (HABD1) and the second HABD (HABD2). The focus was on creating i, i+4
lactam staples throughout the HABDs, positioning the staples between the two basic residues
that make up the essential BX7B motif. After each staple was created, the helicity and
bioactivity of the peptide was evaluated and compared to the linear, unstapled sequence. This
was done in order to identify and assess any stapled RHAMM analogues that may have
potential for therapeutic use for treating diseases that involve HA fragmentation such as
prostate cancer.
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2.2 Results and Discussion
2.2.1

Synthesis of peptides
The effect of synthetic bridging on the degree of α-helicity and the

binding/bioactivity of the truncated binding domains was studied. All peptides were
synthesized by Fmoc solid-phase peptide synthesis (SPPS). The linear sequences were
synthesized using the native amino acid sequence from those portions of the protein (Scheme
2.1).
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Scheme 2.1 - General Fmoc-SPPS method used to synthesize linear peptides to yield
either the acetylated or non-acetylated sequences.

The staple scan was performed to identify the effect of synthetic bridging on the
degree of α-helicity and resulting bioactivity of the truncated binding domains. Cyclization
was carried out by replacing two amino acids within the sequence with glutamic acid and
lysine and creating a lactam bridge between their side chains (Figure 2.1).
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Figure 2.1 – Location for cyclization of peptides using lactam bridge staples (a) cyclic
peptides derived from HABD1. Compound numbers indicated, see Table 2.1 for
structure; (b) cyclic peptides derived from HABD2. Compound numbers indicated, see
Table 2.2 for structure.

The sequences were synthesized by solid-phase peptide synthesis; however, the
glutamic acid and lysine residues were protected by allylester and allyloxycarbonyl
protecting groups respectively. These protecting groups allow for the selective deprotection
of those amino acids using a palladium (0) catalyst so they can subsequently be coupled. The
remaining protecting groups were removed and the lactam-bridged peptide was cleaved from
the solid support to obtain the cyclized peptide sequences (Scheme 2.2).
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Scheme 2.2 - General method showing the formation of the lactam bridge between a
glutamic acid residue and a lysine residue.
Linear and cyclized peptides were synthesized for HABD1, RHAMM(531-541) (Table 2.1)
and the HABD2, RHAMM(553-562) (Table 2.2). All peptides (with the exception of
compounds 7-11) were carboxyamidated and N-terminal acetylated to maintain a neutral
charge at the termini, allowing them to better mimic the native protein22. Compounds 7-11
have a free, charged N-terminus in order to study the effects of this charge on helicity and
binding. All peptides were purified and characterized by LC-MS.
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Table 2.1 - Sequences of binding domain one (HABD1) where (i, i+4) staples were
placed in cyclized versions. Mean residue ellipticity values at 222 nm, ratios of mean
residue ellipticities at 222/208 nm and percentage helicity that were determined at
20°C.
Water
Sequence

[θ]222 x103

[θ]222/

%

[θ]208

Helicity

%

[θ]208

Helicity

-1.14

0.11

6.3

-12.42

0.74

40.3

-2.45

0.38

6.9

-12.49

0.80

44.5

-2.82

0.43

8.2

-12.43

0.84

38.0

-2.61

0.44

7.8

-12.55

0.85

40.8

-3.84

0.55

11.1

-14.22

0.86

42.5

-1.79

0.31

19.1

-16.02

0.82

41.5

cm2/dmol)

2

3

4

5

6

Ac-NLKQKIKHVVKLKDE-NH2
cyclo-4,8(AcNLK[EKIKK]VVKLKDE-NH2)
cyclo-5,9(AcNLKQ[EIKHK]VKLKDE-NH2)
cyclo-6,10(AcNLKQK[EKHVK]KLKDE-NH2)
cyclo-7,11(AcNLKQKI[EHVVK]LKDE-NH2)
cyclo-8,12(AcNLKQKIK[EVVKK]KDE-NH2)

[θ]222 x103

[θ]222/

(deg

1

40% TFE/Water

(deg
cm2/dmol)
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Table 2.2 - Sequences of binding domain two (HABD2) where (i, i+4) staples were
placed in cyclized versions. Mean residue ellipticity values at 222 nm, ratios of mean
residue ellipticities at 222/208 nm and percentage helicity that were determined at
20°C.
Water
Sequence

[θ]222 x103

[θ]222/

%

[θ]208

Helicity

%

[θ]208

Helicity

-1.07

0.21

16.5

-10.5

0.68

39.5

-2.26

0.45

15.8

-8.56

0.72

36.2

-4.40

0.57

21.7

-10.32

0.79

52.6

-4.34

0.58

22.6

-10.09

0.81

51.3

-1.53

0.30

23.1

-9.52

0.69

33.3

-1.10

0.23

14.8

-11.4

0.72

40.9

-3.34

0.53

14.6

-9.75

0.81

37.0

-6.45

0.70

25.5

-13.33

0.82

51.2

-4.85

0.61

28.0

-11.86

0.79

44.8

-2.96

0.54

16.3

-10.53

0.74

34.9

-0.97

0.20

5.5

-8.78

0.75

36.3

-1.98

0.37

8.2

-12.84

0.75

52.2

cm2/dmol)

8

9

10

11
12
13

14

15

16

17

18

H-VSKLRSQLVKRKQN-NH2
cyclo-4,8(HVSK[ERSQK]VKRKQN-NH2)
cyclo-5,9(HVSKL[ESQLK]KRKQN-NH2)
cyclo-6,10(HVSKLR[EQLVK]RKQN-NH2)
cyclo-7,11(HVSKLRS[ELVKK]KQN-NH2)
Ac-VSKLRSQLVKRKQN-NH2
cyclo-4,8(AcVSK[ERSQK]VKRKQN-NH2)
cyclo-5,9(AcVSKL[ESQLK]KRKQN-NH2)
cyclo-6,10(AcVSKLR[EQLVK]RKQN-NH2)
cyclo-7,11(AcVSKLRS[ELVKK]KQN-NH2)
cyclo-5,9(AcVSKL[KSQLE]KRKQN-NH2)
cyclo-6,10(AcVSKLR[KQLVE]RKQN-NH2)

[θ]222 x103

[θ]222/

(deg

7

40% TFE/Water

(deg
cm2/dmol)
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Cyclization of the HABDs was achieved though the formation of a lactam bridge
between two amino acid side chains. Glutamic acid was placed in the i position and lysine in
the i+4 position in order to create a ring size of 21 atoms. These amino acids were used for
creating the lactam bridge as it has been reported that lactam bridges forming 21-membered
rings are α-helix-inducing, while 19-membered rings are α-helix destabilizing23. Therefore,
cyclization in this way should allow the peptide to more easily overcome the high-energy
barrier required to form an α-helix.
The composition of the staple has been reported to affect the properties of cyclized
peptides; therefore the placement of the lysine and glutamic acid residues in the staple was
evaluated. For cyclic lactams, peptides are most helical when the glutamic acid is in the i
position and lysine is in the i+4 position24. The composition of the staple was reversed in the
two peptides from HABD2 that were found to have the greatest induced helicity (14 and 15).
These peptides (17 and 18) contained a staple that was constructed by a lysine residue in the i
position and a glutamic acid residue in the i+4 position.

2.2.2

Helicity analysis of cyclization by circular dichroism

spectroscopy
Cyclized sequences have been shown to have greater helicity and a corresponding increase in
bioactivity23,25–29. The synthesized sequences were analyzed by CD spectroscopy in order to
determine the degree of α-helicity present in each peptide. A mean residue ellipticity ratio
([θ]222/[θ]208) that is ~1.00 indicates high α-helical character, while a lower ratio implies that
the conformation could contain a combination of an α-helix and a β–sheet or random coil26,30.
The molar ellipticity ratios and the quantification of helicity for HABD1 and HABD2 can be
found in Table 2.1 and Table 2.2, respectively.
The linear, unstapled peptides (1, 7, 12) show minimal α-helical character in water.
This was expected, as there is a lack of residues that could contribute to a hydrophobic core,
which would result in a stabilized secondary structure7. However, when the same sequences
were tested in 40% TFE solution, a higher [θ]222/[θ]208 ratio was observed, with 1, 7, and 12
having values of around 0.75, suggesting the formation of an α-helical structure. This is due
to the natural propensity of the sequence to adopt a helical shape, as the TFE facilitates the
peptide’s folding18. It is assumed that the [θ]222/[θ]208 ratio of the linear sequences in the
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presence of 40% TFE is the theoretical maximum helicity that these synthetic sequences can
possess.
The HABD1 did not achieve as substantial of an increase in helicity when the staples
were introduced compared to the improvements seen when the staple was placed in HABD2
(Figure 2.2). This can be seen by the larger minima seen with the stapled peptides in HABD2
compared to that of their linear counterparts. This difference between binding domains could
be due to the differences in their primary sequences. HABD2 has more leucine and glutamine
residues in its primary sequence than HABD1, and those residues are proposed to be helixstabilizing residues26. Without these residues in the sequence, the α-helical structure may
become less stable and therefore result in a weaker α-helical signal.
b
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Figure 2.2 - (a) CD spectra of linear unstapled sequence of HABD1 (1) and the cyclic
versions (3 and 5) that showed the greatest increase in helicity; (b) CD spectra of linear
unstapled sequence of HABD2 (12) and the cyclic versions (14 and 15) that showed the
greatest increase in helicity.
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The stapled peptides of HABD1 resulted in an increase in helicity when compared to
the linear sequence. This was determined by the increase in the molar ellipticity at 222 nm
(Figure 2.3; a) and the minimum moving closer to 208 nm, which is characteristic of an αhelix. Comparing the molar ellipticity ratios demonstrates that the values of the stapled
peptides (2-6) in water are greater than that of the unstapled sequence (1) (Figure 2.3; b). The
greatest [θ]222/[θ]208 ratio for the cyclic peptides from HABD1 was compound 5. The
sequence has a [θ]222/[θ]208 ratio of 0.55 which approaches 0.74, which is the [θ]222/[θ]208
value of the unstapled sequence (1) in the presence of 40% TFE.
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Figure 2.3 - (a) Comparison of CD spectra of the linear sequence of HABD1 (1) and the
cyclized sequence (2-6) in water; (b) Comparison of [θ]222/[θ]208 values for the sequences
(linear and cyclized) that derive from HABD1.

There was a greater increase in induced helicity of HABD2 when the stapled were
introduced to the sequence (Figure 2.4; a) than seen in HABD1. Cyclizing this sequence
creates a CD signal that has a greater minimum at 222nm, as well as a larger maximum at
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192nm, both indicators of α-helicity. When the [θ]222/[θ]208 ratio from the linear peptide
sequence is compared to the cyclized versions, the ratios for the cyclized sequences in water
are comparable to the value of the linear counterpart in 40% TFE (Figure 2.4; b). The
cyclized peptides in water alone achieve similar [θ]222/[θ]208 ratios as the theoretical
maximum obtained by the linear counterpart in 40% TFE/water, indicating that the staple is
helping induce the maximum helicity possible for this sequence.
b
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Figure 2.4 - (a) Comparison of CD spectra of the linear sequence of HABD (12) and the
cyclized sequences (13-16) in water; (b) Comparison of [θ]222/[θ]208 values for the
sequences (linear and cyclized) that derive from HABD2.

Staple placement within the peptide backbone is important for helicity, and a
maximal increase in α-helical structure was observed in peptides where staples were
introduced towards the center of the peptide (14 and 15). However, the staples placed near
the termini of the peptides (13 and 16) do not stabilize the core of the peptide and do not
facilitate the formation of a complete α-helical conformation. Differences in α-helicity
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induced by the staples placed at different points within each peptide may be due to the
changes made to their primary sequences, since two amino acids (in the i and i+4 positions)
must be substituted in order to form the lactam bridge. In compound 13, leucine was replaced
at both the i and i+4 position, while in compound 16, glutamine was replaced at the i position
and arginine was replaced at i+4. Leucine and glutamine are proposed to be helix-stabilizing
residues26 and the loss of these amino acids may contribute to the lower helicity.
During the assessment of HABD2, the positioning of the amino acids that compose
the staple were reversed in two instances to observe its effect on the formation of an α-helix.
It was noted that when lysine was in the i position and glutamic acid in the i+4 position (17
and 18), their molar ellipticity ratios were 0.20 and 0.37 respectively. This ratio is greatly
decreased compared compounds 14 and 15 (0.70 and 0.61, respectively), as these sequences
have the same staple position, just different staple composition. Compound 14 was 3.5 times
more helical than 17, a trend that is also seen between 15 and 18, as 15 was 1.6 times more
helical than 18.

2.2.3

In vitro stability of peptides
Peptides are susceptible to degradation in-vivo due to their natural composition;

however, pre-forming the helix by introducing the lactam bridge can reduce exposure of the
vulnerable amide backbone and increase resistance to protease cleavage31. For these reasons,
all peptides were subjected to a human serum stability analysis to evaluate the effect of staple
positions on the peptides’ stability.
The shortest half-life was seen for Compound 7 at 220 minutes. This was expected, as
it is a linear peptide with a free N-terminus. However, when the sequences were cyclized, but
still had a free N-terminus (compounds 8-11), no significant breakdown was observed after
24 hours. The remaining peptides studied were C and N-terminus capped, both linear and
cyclized and these peptides displayed no degradation over 24 hours, regardless if they were
cyclized. It has previously been reported that the combination of N-terminal acetylation and
carboxyamidation increases a peptide’s resistance to protease degradation32.
To assess the effectiveness of the staple in interfering with trypsin degradation of the
peptides, a trypsin assay was run on compounds 12 and 15. As expected, hydrolysis was
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found to preferentially occur at Arg and Lys residues near the C-terminus in peptides 12 and
15. The major, initial trypsin hydrolysis sites of 12 were at the carboxyl-terminus of Lys-3
and Arg-5, and at Lys-10 to a lesser degree. The half-life of peptide 12 towards trypsin
degradation was determined to be 0.5 minutes, while the introduction of the lactam bridge in
15 significantly improved the peptide’s stability towards trypsin, as the half-life improved to
30 minutes. Hydrolysis of 15 differed from 12 such that digestion did not occur at Arg-5 or
Lys-10, the latter of which forms a portion of the lactam bridge of 15. The major, initial
trypsin hydrolysis sites of 15 were at carboxy-terminus of Lys-3, and Arg-11 to a lesser
degree.

2.2.4

Ability of peptides to bind hyaluronan
Due to α-helical character being important to the RHAMM protein for binding to HA,

it was hypothesized that an improvement in helicity of the stapled peptides over their linear
counterpart would also increase their ability to bind HA. To test the peptides’ binding, either
biochemical or biophysical assays can be used. Biochemical assays, such as ELISA, allow
for a small amount of the protein target to be used and can be useful in a high-throughput
assay33. However, direct binding measurement of these peptides to HA using an ELISA
would require tagging of the HABD mimics with a tag molecule, such as biotin, to generate a
signal. This has the potential to change how the peptide interacts with HA, which
undesirable. The use of a biophysical screening method such as surface plasmon resonance
(SPR) allows for a low to medium throughput screening33, but is an ideal method of
measuring binding, as it does not require modification of the peptides in order to test direct
binding to HA. To use SPR, 5-10 kDa HA was modified by reductive amination of the
anomeric carbon with cystamine following a published procedure34 (Scheme 2.3).
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Following modification, HA was bound to the surface of the gold chip to be used in
the SPR experiments. Unmodified peptides were passed over the surface at varying
concentrations in order to obtain the binding kinetics and the absorbance readings of each
peptide were also plotted together to compare their signals intensities at identical
concentrations (Figure 2.5).
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Figure 2.5 - SPR binding curves for peptides from (a) HABD1 or (b) HABD2 that were
passed over HA-coated gold chip at a concentration of 25 µM.
The KD values were obtained for all of the peptides mimicking HABD1, all acetylated
peptides from HABD2, and the non-acetylated peptides 7 and 10, in order to determine the
effect of acetylation on the peptide’s binding to HA (Table 2.3).
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Table 2.3 - Sequences from both HABD1 and HABD2 and the calculated KD values
determined by SPR.
Cmpd

Binding Domain

Sequence

KD (µM)

1

Ac-NLKQKIKHVVKLKDE-NH2

59.8

2

cyclo-4,8(Ac-NLK[EKIKK]VVKLKDE-NH2)

29.6

3

cyclo-5,9(Ac-NLKQ[EIKHK]VKLKDE-NH2)

6.2

4

cyclo-6,10(Ac-NLKQK[EKHVK]KLKDE-NH2)

158

5

cyclo-7,11(Ac-NLKQKI[EHVVK]LKDE-NH2)

332

6

cyclo-8,12(Ac-NLKQKIK[EVVKK]KDE-NH2)

15.7

7

H-VSKLRSQLVKRKQN-NH2

3030

10

cyclo-6,10(H-VSKLR[EQLVK]RKQN-NH2)

12

Ac-VSKLRSQLVKRKQN-NH2

1076

13

cyclo-4,8(Ac-VSK[ERSQK]VKRKQN-NH2)

144

cyclo-5,9(Ac-VSKL[ESQLK]KRKQN-NH2)

4.7

15

cyclo-6,10(Ac-VSKLR[EQLVK]RKQN-NH2)

1.0

16

cyclo-7,11(Ac-VSKLRS[ELVKK]KQN-NH2)

22.2

17

cyclo-5,9(Ac-VSKL[KSQLE]KRKQN-NH2)

158

18

cyclo-6,10(Ac-VSKLR[KQLVE]RKQN-NH2)

156

1

14

2

1.9

The linear sequence from HABD1 (1) bound to HA more strongly than the linear
sequences from HABD2 (7 and 12). However the introduction of the staples in HABD1
decreased binding to HA in some cases (4 and 5). Compound 3, however, showed a
significant increase in binding. This might be because the residues that were switched out to
allow formation of the lactam bridge in 4 and 5 were essential for binding, where the
modified amino acids in compound 3 were not important for HA-RHAMM interactions.
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The introduction of the staples to HABD2 caused an improvement in binding in all
cases. In this binding domain, a positive correlation was seen between the mean residue
ellipticity ratio and the peptide’s ability to bind to HA. Compounds 14 and 15 showed the
greatest induction of helicity, as well as the greatest increase in binding compared to the
linear sequence. Also, when the Lys and Glu residues were reversed (compounds 17 and 18),
the binding to HA decreased compared to their similar sequences 14 and 15. This was a trend
that followed what was seen via CD spectroscopy, as the helicity was also decreased when
the lactam bridge was switched from a Glu – Lys to a Lys – Glu. It was also observed that
the N-terminally acetylated sequences (12 and 15) had better binding compared to those that
had a free N-terminus (7 and 10).

2.2.5

In vitro bioactivity
It has been established that RHAMM regulates cell motility and stem cell

differentiation10. These functions have been linked to HA binding capability of RHAMM,
and to its intracellular association with proteins such as ERK and tubulin. For this reason, all
peptides were tested in vitro to evaluate their biological activity and identify any correlation
between bioactivity and helicity. High expression levels of RHAMM has been shown to be
positively correlated with cellular migration, inflammation, and fibrosis35. Therefore, we
evaluated our peptides in functional assays relating to these cellular responses. The stapled
peptides have been designed to mimic RHAMM, and therefore should interact with HA and
prevent the RHAMM:HA fragment interaction from occurring. The stapled sequence from
each binding domain that showed the highest binding to HA according to SPR analysis for
both binding domains were analyzed for their ability to inhibit cellular migration (Figure
2.6).
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Figure 2.6 – The inhibition of cellular migration of LR21 cells overexpressing RHAMM
assessed by a Boyden Chamber assay. Assay was performed at a 10 µg/mL
concentration of the linear and best cyclic peptides from each binding domain. The
positive control (no added peptide), which showed minimal inhibition of cellular
migration, was also measured (UT). (*p<0.05; ***p<0.001)

LR21 cells overexpressing RHAMM were used in a Boyden Chamber assay to assess
the ability of cells to migrate through pores to the chemoattractant below. When only serum
is present, cells can actively migrate through the pores. However, in the presence of bioactive
peptides, there is an inhibitory effect on the cell, resulting in a decrease in migration.
Compound 15 had a greater inhibitory effect on cell migration than 12, as seen in Figure 2.6,
which may be linked to its propensity to form an α-helix compared to other peptides studied,
indicating a direct correlation between HABD2’s helicity and bioactivity. Based on these
results, HABD1 did not have a significant inhibition of cellular migration while compound
15 did (p<0.001). For this reason, all inflammation and fibrosis assays were carried out on
the HABD2 linear and cyclic sequences. The ability of 15 to reduce inflammation and
fibrosis relative to the linear sequence 12 was then assessed (Figure 2.7).
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Figure 2.7 - (a) Inflammation assay run with RAW 264.7 macrophages carrying a
SEAP reporter to assess the inhibition of release of inflammatory markers; (b) Fibrosis
assay performed with IMR90 human fetal lung fibroblasts to assess the inhibition of
fibrosis markers. The positive control (no added peptide), which showed minimal
response in both assays, was also measured (UT). (**p<0.01)

Inflammation plays a key role in cancer, as it has been shown that cancer growth and
spread can be accelerated through the intrusion of lymphocytes36. NF-κB is an inflammatory
response that is released from macrophages when they are stimulated with pro-inflammatory
signals such as PAM3CSK4. It has been observed that there is increased RHAMM
expression in macrophages when there is tissue injury35. The results have shown a significant
increase in inhibition of inflammation when 15 is added (p<0.01), while there is not a
significant inhibitory effect with 12. This indicates that the cyclic RHAMM mimetic (15) is
able to inhibit the release of NF-κB (Figure 2.7; a), signifying it may be possible for this
peptide to decrease the accumulation of macrophages, and thus inflammation, within injured
tissue (i.e. a tumor).
There is an increase in TGF-β1 production from fibroblasts when there is an injury to
the tissue. This increase in TGF-β1 can also up-regulate the production and deposition of HA,
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leading to increased fibrosis35. However, RHAMM:HA interactions are needed in order for
there to be TGF-β1-stimulated cell locomotion, which would allow for this increase in HA
production. The fibrosis assay showed that there is a significant decrease in production of
fibrosis markers upon introduction of 15 (p<0.01), indicating there is less in vitro fibrosis
occurring. Through comparison of the in vitro assays, peptide 15, which has a 3-fold increase
in helicity compared to the linear sequence, was able to inhibit a wide range of cellular
functions.

2.3 Conclusion
Peptides containing either HABD1 or HABD2 of RHAMM were synthesized and
chemically modified in order to stabilize the compounds’ α-helicity. These peptides were
stapled at various i and i+4 positions along the peptide’s primary sequence as a means of
constraining the peptide, thus limiting the number of possible conformations that it could
adopt. Fifteen cyclic peptides were designed and synthesized to mimic the HA binding
domains of RHAMM. CD spectroscopy was used to analyze and quantify the degree of αhelicity that the staples introduced in comparison to their unstapled counterpart. It was
observed that the unstapled peptide had minimal α-helicity in water, as was expected, and
that compounds 14 and 15 from HABD2 had a greatly improved degree of α-helical
conformation. It was seen that these stapled peptides had improved serum stability and
increased resistance to trypsin compared to the unstapled sequence. There was a positive
correlation between helicity of the cyclic peptides from HABD2 and their ability to bind to
HA, but the same trend was not observed with HABD1. The best cyclic compound, 15, has
the potential to be a cancer therapeutic, as it is able to decrease cell migration, inflammation,
and fibrosis. It has the potential to help decrease the metastases of a primary tumor, leading
to the potential reduction in the mortality of cancer. We will continue optimize these lead
compounds and will develop additional in vivo assays for further evaluation.

2.4 Experimental
2.4.1

General information

All Fmoc-protected amino acids were obtained from ChemImpex. HCTU, HATU, and Rink
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Amide

MBHA

Resin

(4-(2’,4’-dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-

aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl benzhydrylamine resin) were obtained
from ChemImpex. Tetrakis(triphenylphosphine)palladium(0), phenylsilane, Fmoc-AEEA
spacer, and NHS-Biotin were obtained from Sigma-Aldrich. All solvents were obtained from
Fischer Thermo-Scientific.

2.4.2

Solid-phase peptide synthesis

Fmoc-based solid-phase synthesis was carried out by either manual synthesis using a fritted
glass peptide vessel or by automated synthesis using a Biotage® Syro Wave™ automated
peptide synthesizer. Synthesis was performed on a 0.1 mmol scale with 0.52 mmol/g FmocRink amide MBHA resin and a 3-fold excess of the protected amino acids. The resin was
swelled in CH2Cl2 (2.0 mL, 15 minutes) then rinsed with DMF (1.0 mL, 1 min). Fmoc
deprotection was performed with a solution of 20% piperidine/DMF (1.5 mL) 5 minutes,
then washed with three times with DMF (2.0 mL, vortex 30 seconds) and then again for
15min with 20% piperidine/DMF (1.5 mL). The resin was further washed with DMF six
times (2.0 mL, vortex 30 seconds). A Kaiser test was performed after the Fmoc removal to
verify the presence of a free primary amino group. Fmoc-protected amino acid (0.3 mmol)
and HCTU (0.3 mmol) was dissolved in DMF (1.5 mL) and added to the resin. The mixture
was vortexed for 30 seconds and then DIPEA (0.6 mmol) was added to the mixture and
vortexed for 1 hour. The deprotection/amino acid coupling cycle was repeated until the
desired amino acid sequence was obtained. After the final amino acid was coupled, the resin
was washed with DMF (3x) and CH2Cl2 (3x) and then dried under vacuum and stored in the
freezer (-20 ᴼC). Removal of the N-terminal Fmoc protecting group was achieved using the
previously described deprotection procedure. Cleavage of the peptide from the resin and side
chain protecting groups was performed by adding a solution of 95% trifluoroacetic acid/2.5%
triisopropylsilane/2.5% water (3 mL) to the resin and vortexing for 4-5 hours. After filtration,
the peptide was precipitated with cold tert-butyl methyl ether (TBME) (20 mL) and collected
by centrifugation. The mother liquor was decanted, the pellet dissolved in water (20mL) and
lyophilized to obtain the crude fully deprotected peptide.
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2.4.3

Deprotection of the allyloxycarbonyl (Alloc) and allylester (OAll)

protecting groups
Selective deprotection of the allyloxycarbonyl and the allylester protecting groups was
accomplished by adding CH2Cl2 (4.5 mL) to the resin-bound peptide and shaking gently for
10 minutes. After addition of phenylsilane (24 eq), the peptide vessel was flushed with
nitrogen for 5 minutes. Tetrakis(triphenylphosphine) palladium (0) (0.1 eq) was then added
to the mixture and the peptide vessel was again flushed with nitrogen, and the reaction was
allowed to proceed for 10 minutes. The peptide-resin was washed with CH2Cl2 (4 x 30
seconds), followed by a series of washings with CH2Cl2, DMF, MeOH, DMF, and CH2Cl2
(30 seconds each).

2.4.4

Lactam bridge formation

After selective deprotection of alloc and allyl ester groups, HATU (3 eq) was dissolved in
DMF (1.5 mL), added to the resin and vortexed for 30 seconds. DIPEA (6 eq) was then
added and the reaction was vortexed for 2 hours. The resin was rinsed with DMF and CH2Cl2
(2.0 ml, 3 x 30 seconds each) to remove any residual reactants.

2.4.5

Purification by RP-HPLC/ESI-MS

Peptides were analyzed using a reverse-phase analytical HPLC column (Agilent Zorbax SBC18 column 4.6 x 150 mm, 3.5 µm). This system was equipped with a Waters 600E
Multisolvent Delivery System, Waters 600 controller, Waters inline degasser, and Waters
Masslynx software (version 4.1). Employed mobile phases were 0.1% TFA in Milli-Q water
(eluent A) and 0.1% TFA in acetonitrile (eluent B). The flow rate was set at 1.5 mLmin-1
with a gradient elution over a 12 minute gradient. The column eluent was monitored using a
Waters 2998 Photodiode array detector. Peptides were purified using a reversed-phase
preparative HPLC column (Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 µm) on the
same system described above. The detection method and eluents were the same as the
analytical system, with the flow rate was set at 20 mLmin-1. The collected fractions were then
lyophilized to a solid and analyzed by ESI-MS. Purity of final products was determined by an
Acquity UHPLC-MS (220 nm).
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2.4.6

Circular dichroism (CD) spectroscopy

CD spectra were obtained on a Jasco J-810 spectropolarimeter and recorded in the range of
180-260 nm. Peptide solutions were prepared with a 0.1 M phosphate buffer solution to a
concentration of 0.5 mM. The measurements were performed in quartz cuvettes with a path
length of 1 mm and a scanning speed of 10-50 nm/min. Five individual data points were
averaged by the instrument in order to obtain the reported CD spectrum. The measurements
were carried out at 20 ᴼC. A blank solution of 0.1 M phosphate buffer solution was run
before every measurement in order to baseline correct for any UV-interference observed
from the buffer. Deconvolution of CD spectra were obtained using the CONTINLL program,
which is part of the web-based program CdPro (http://lamar.colostate.edu/~sreeram/CDPro/).

2.4.7

Surface plasmon resonance

HA was modified using a literature procedure, with some modifications34. 5-10kDa HA (40
mg) was dissolved in DMSO/H2O (7/3, v/v) with an excess amount of sodium
cyanoborohydride added. This solution was allowed to stir for 12 hours at room temperature,
10 eq of cystamine was added and the mixture was allowed to stir for a further 24 hours. The
solution was then added to a dialysis membrane (MWCO 3.5-5 kDa) where the by-products
were removed by dialysis for 3 days followed by lyophilization until a white powder was
obtained. SPR experiments were performed with an openSPR (Nicoya Lifesciences,
Waterloo, Canada) at 25°C with a 100 µL loading loop and a constant flow rate of 50
µL/min. The cystamine-modified HA was added to a functionalized gold chip by dissolving
HA-cystamine (1 mg/mL) in water and incubating for 24 hours at 4°C. Binding of the HABD
mimics and the linear sequences were tested in a 10mM solution of phosphate buffered saline
(137 mM NaCl, 2.7 mM KCl, 10mM Na2HPO4, 2 mM KH2PO4). The peptides were injected
over the bound HA in concentrations from 1 µM to 1 mM for 2 min to allow association. 10
mM PBS was passed over the sensor for 8 min to allow dissociation. After each peptide
injection, 1 mM NaCl was injected to completely dissociate the complex and regenerate the
HA surface. Data analysis was performed using Trace Drawer software (Ridgeview
Instruments AB) as recommended by the manufacturer. Kinetic parameters were calculated
using global analysis, fitting the data to a simple 1:1 model.
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2.4.8

Serum stability

Each peptide (1 mM final concentration) was incubated in a mixture of 25% human serum
(Sigma-Aldrich, Male type AB cat# H4522) in PBS (Phosphate buffer saline, pH 7.4, 450 µL
final volume, DMSO final concentration 0.5%) at 37°C. At various time intervals, aliquots of
peptide solution were removed and mixed with either acidic solutions (4% phosphoric acid,
pH 1-2) or basic (4% ammonium hydroxide, pH 11-13) to dissociate peptide interactions
with components of human serum. Peptide was isolated from human serum by column
separation on Oasis® sorbent 96-well µElution plates (HLB- amphiphilic resin and MCXcation exchange resin) and manifold. The extracted peptide was quantified on an Acquity
UHPLC-MS system, by measuring the peak area of a peptide specific M+n ion peak (average
of 3 replicates). Percent abundance of peptide peak area relative to peptide peak abundance at
T0 was plotted as a function of time. Peptide half-life was calculated by optimized curve
fitting (linear, 2-parameter or 3-parameter exponential decay curve) on SigmaPlot™ and
solving for time at 50% peptide peak abundance.

2.4.9

Trypsin assay

Human trypsin was purchased from Sigma-Aldrich (EC# 3.4.21.4). Lyophilized trypsin was
reconstituted in a solution of 1 mM HCl, 10% glycerol, 1 mM 2-mercaptoethanol, aliquoted
and frozen until future use. Assays were carried out with 25 nM trypsin, 250 µM peptide in
67 mM Sodium Phosphate Buffer, pH 7.6 at 37°C. Periodically, aliquots were taken and
trypsin activity quenched with equal volume 50:50 methanol:water, 1 M HCl. Peptide was
quantified on an Acquity UHPLC, combined with a Xevo QTof mass spectrometer (Waters,
Milford, MA.) The UPLC system was equipped with a Waters Acquity UHPLC BEH C18
2.1 x 50 mm, 1.7 µm column; samples were run with a gradient of 5 to 40% water + 0.1%
formic acid : acetonitrile + 0.1% formic acid for four minutes. Mass analysis was carried out
in electro-spray ionization positive (ESI+) mode. Peptide and trypsin digest products were
quantified by M/Z peak area analysis. Data was normalized to peptide abundance at T0, and
half-life was measured by curve-fitting and solving for 50% abundance. Trypsin assays were
carried out in triplicate. Trypsin activity towards a control substrate, 250 µM Nα-benzoyl-LArginine Ethyl Ester (BAEE), was run before each test to confirm enzyme activity.
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2.4.10

Cell migration assay

Cell migration assay was performed using Chemicon Assay Kits (ECM510, ECM555;
Billerica, MA, USA) according to manufacturer’s protocol. Briefly, sub-confluent cultures of
RHAMM-overexpressing (LR21) cells were serum-starved overnight before plating 7.5x104
cells in the upper chamber of the Boyden chamber either in the presence or absence of 10
ng/mL of peptide. 30% fetal bovine serum in DMEM was used as the chemo-attractant in the
lower chamber. The number of cells that had crossed the membrane after 20 hours was
assessed using the CyQUANT® GR Dye and lysis buffer solution provided in the kit.
Fluorescence was measured with a fluorescent plate reader using a 480/520 nm filter set.

2.4.11

RAW-blue macrophage reporter assay

To determine the effect of various peptides on inflammation, commercially available murine
RAW 264.7 macrophages carrying a SEAP reporter that is inducible by NF-κB (RAW-Blue;
InvivoGen, San Diego, CA, USA) were used. Cells were grown to 80% confluence in
DMEM containing 4.5 g/L glucose, 10% heat-inactivated fetal bovine serum, 2 mM Lglutamine, 50µg/mL penicillin/streptomycin, 100 µg/mL Normocin (InvivoGen) at 37°C in
5% CO2. For peptide screening experiments, cells were scraped in growth medium, counted,
and plated to flat-bottom 96-well plates at a density of 5x104 cells/well either in the presence
or absence (control) of 200 ng/mL TLR1/TLR2 agonist PAM3CSK4 (InvivoGen). RHAMM
peptides were added in 6 replicate wells at a dose of 10 ng/mL in the presence of
PAM3CSK4. After 18 hours of stimulation, SEAP concentrations (indicating NF-κB activity)
were measured in the supernatants collected from the RAW-Blue cells using QUANTI-Blue
reagent (InvivoGen). After 20 minutes of incubation at 37°C, SEAP levels were determined
using spectrophotometry at a wavelength of 630 nm.

2.4.12

TGF-β-induced fibrosis assay

IMR90 human fetal lung fibroblasts were obtained from ATCC and maintained in DMEM
supplemented with 10% fetal bovine serum. In order to examine the effect of RHAMM
peptides on myofibroblast differentiation, 80% confluent cultures were serum starved
overnight prior to addition of TGF-β (2 ng/mL, R&D Systems). Cells were treated with TGFβ for 24 hours prior to addition of RHAMM peptides (10ng/mL). 48 hours after addition of

39

peptides, culture supernatants were collected and levels of active TGF-β measured using
commercially available TGF-β ELISA (Quantikine, R&D Systems).
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Chapter 3

3

Structure activity relationship studies of cyclic peptides
comprised of the second hyaluronan binding domain of
RHAMM

3.1 Introduction
3.1.1

Difference between Mus musculus and Homo sapiens
sequences
The use of Mus musculus in research is a practice that dates back to 19101. This is

because M. musculus and Homo sapiens share a common ancestor, allowing for a high
degree of homology between the genomes2. Approximately 80% of genes within the M.
musculus sequence have a single homologue in the H. sapiens genome, with both genomes
encoding for approximately 30,000 proteins2. This homology allows for the translation of
results from mouse models to humans. In the previously described work, in which the
secondary structure of the hyaluronan binding domains (HABDs) of the receptor for
hyaluronan mediated motility (RHAMM) were stabilized by cyclization, the RHAMM
sequences that were used were drawn from the genome of M. musculus. The M. musculus
and H. sapiens sequences of full length RHAMM have 85 percent homology, with HABD1
having 100 percent homology and HABD2 having 71 percent homology with two
conservative changes3 (Figure 3.1).

633 NLKQKIKHVVKLKDENSQLKSEVSKLRCQLAKKKQS 669
NLKQKIKHVVKLKDENSQLKSEVSKLRCQLAK+ KQ+
716 NLKQKIKHVVKLKDENSQLKSEVSKLR SQLVKRKQN 752
Figure 3.1 - Sequences of RHAMM from Homo sapiens (top) and Mus musculus
(bottom). HABD1 is highlighted in red and HABD2 is highlighted in green. The
homologous sequences are seen (middle) with non-conserved changes seen as a blank
and a conserved change as a +.3
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The H. sapiens sequence was not originally used for the HABD modifications, as the
second hyaluronan binding domain (HABD2) sequence contains a cysteine residue (position
744). Cysteine can cause issues during solid-phase peptide synthesis due to racemization
during coupling steps or formation of intermolecular disulfide bonds via oxidation4. These
problems can be avoided by using alternative coupling reagents or by removing the cysteine
residue from the sequence. Therapeutics containing free thiols can result in oxidation before
or after administration of the drug, therefore changing its composition and potential effects5.
Changing the cysteine to another amino acid (such as serine in the M. musculus sequence)
would eliminate this problem and would provide a more stable drug for in vivo use. In order
to identify the impact that this sequence change to H. sapiens would have on binding to
hyaluronan (HA), its effect on helicity and binding was investigated.

3.1.2

Identifying essential residues for binding
The hyaladherin group of proteins, which all bind HA, have a conserved binding

region that can provide insight on how these proteins interact with this polysaccride6. The
binding regions of the hyaladherins include the previously mentioned BX7B binding motif,
where seven non-acidic residues separate two basic residues in order to provide adequate
spacing6. There are four basic residues within HABD2; if helicity can be introduced in this
sequence via cyclization of two amino acid side chains, the basic residues are likely to be
positioned more optimally, facilitating interaction with HA. However, if only two basic
residues are needed to provide the proper BX7B motif remains, it would allow for further
peptide modifications and ultimately an improved sequence with increased affinity to HA.
Reducing the number of positively charged residues may also be beneficial for future
development of this cyclic peptide as a therapeutic.
Alanine scans are a method used to identify the necessary residues for functional
activity of a peptide, such as target binding or bioactivity. An alanine scan involves creating
a series of peptides in which one amino acid in the sequence is replaced with alanine, and
comparing the activity of the alanine-containing sequences to the parent sequence. This has
been used to yield important functional information and can provide insight into how the
parent sequence can be further modified to increase activity7–9. Alanine is utilized because its
side chain does not continue past the β-carbon, and therefore determines whether the side
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chain of the replaced amino acid is important for bioactivity7. Alanine is a helix-stabilizing
residue; however, the loss of the side chain functionality may disrupt the secondary
structure10. An alanine scan was completed on the lead helical lactam-bridged peptide (15) to
identify which basic residues were essential for binding to HA, as well as to determine how
the positioning of those positive charges in the sequence affects binding to HA.

3.2 Results and Discussion
3.2.1

H. sapiens sequence
The linear and the cyclized version of the H. sapiens RHAMM sequence were

synthesized to compare them to the M. musculus sequence reported in Chapter 2 (Table 3.1).
These peptides were synthesized as previously mentioned through solid phase peptide
synthesis. However, when cleaving the linear peptide from the resin, dithiothritol (DTT) was
employed due to the presence of cysteine. DDT is a redox reagent that will help reduce the
chance of the oxidation of the thiol or the formation of intermolecular bonds during the
reaction.
Table 3.1 - H. sapiens linear and cyclized (i, i+4) sequences of HABD2. Both sequences
were amidated on the C-terminus and acetylated on the N-terminus. Mean residue
ellipticity values at 222 nm, ratios of mean residue ellipticities at 222/208 nm and
percentage helicity at 25°C are reported.
Water
Cmpd

Sequence

Species
θ222/θ208

12

Ac-VSKLRSQLVKRKQN-NH2

Water/40% TFE
%

Helicity

θ222/θ208

%
Helicity

0.23

14.8

0.72

40.9

0.61

28.0

0.79

44.8

0.22

22.9

0.75

79.6

0.79

82.5

0.86

91.6

M.
15
19

cyclo-6,10(Ac-

musculus

VSKLR[EQLVK]RKQN-NH2)
Ac-VSKLRCQLLAKKKQS-NH2
H.

20

cyclo-6,10(AcVSKLR[EQLAK]KKQS-NH2)

sapiens
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The helicity of the H. sapiens sequences (19 and 20) was evaluated and compared
with their M. musculus equivalents (12 and 15). The H. sapiens linear sequence (19) has
comparable percent helicity to the linear sequence of M. musculus (12). However, the
cyclized version of H. sapiens (20) has an increase in helicity over the M. musculus (15),
which might be due to the non-conserved amino acids aiding in helical formation. When
examining the CD spectra of the compounds, the H. sapiens sequence (20) has greater
minima at 222 nm and 208 nm than compound 15 (the M. musculus sequence), which is

Mean Residue Ellipticity (deg cm2/dmol)

indicative of greater α-helical character (Figure 3.2).
1.50E+04
1.00E+04
5.00E+03
0.00E+00
180 190 200 210 220 230 240 250 260
-5.00E+03
-1.00E+04
-1.50E+04
-2.00E+04

Wavelength (nm)
12

15

19

20

Figure 3.2 - CD spectra of the linear and cyclized sequences from M. musculus (12 and
15) compared with the linear and cyclized sequences from H. sapiens (19 and 20).

The peptides were evaluated for their ability to bind HA, as it was hypothesized that
an increase in helicity would correlate to an increase in binding affinity. Both linear
sequences (12 and 19) showed comparable binding to HA, while the cyclized peptide from
M. musculus (15) still exhibited the strongest binding interaction (Figure 3.3).

48

240

Signal

190
140
90
40
-10

0

100

200

300

400

500

600

Time (seconds)
12

19

15

20

Figure 3.3 - SPR binding curves for both M. musculus sequences (12 and 15) and H.
sapiens sequences (19 and 20) that was passed over HA-coated gold chip at a
concentration of 25 µM.

The binding affinities were determined from the SPR data, and it can be observed that
cyclizing the H. sapiens sequence (20) did improve the binding when compared to the linear
counterpart (19), but affinity was not as the cyclized peptide derived from M. musculus (15)
(Table 3.2).
Table 3.2 - The calculated KD values determined by SPR for the M. musculus and H.
sapiens sequences from HABD2.
Cmpd
12
15
19
20

Species
M. musculus

H. sapiens

KD (µM)
1076
1.0
1660
16.2

The HABD2 sequences of H. sapiens and M. musculus are 71 percent homologous,
but the differences have an effect upon binding to HA. Despite there being an increase in
helicity, the conformation of the H. sapiens sequence might not permit for the proper
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orientation of the binding residues; for instance, these residues might not be solvent exposed,
causing a decrease in binding.

3.2.2

Alanine scan to identify essential binding residues
An alanine scan was completed in order to identify the essential binding residues

within compound 15. This involved the replacement of two of the four basic residues in the
sequence with alanine residues, resulting in only one basic residue on either side of the staple
(Table 3.3). If only one basic residue at a time was replaced with alanine, then there is the
potential for the remaining basic residues to mask the contribution of the lost residue.
Table 3.3 - Comparison of the helicity of compound 15 and the resulting sequences
resulting from the alanine scan of its basic residues (21-24). All sequences were
amidated on the C-terminus and acetylated on the N-terminus. Mean residue ellipticity
values at 222 nm, ratios of mean residue ellipticities at 222/208 nm and percentage
helicity that were determined at 20°C.
Water
Cmpd

Sequence
θ222/θ208

Water/40% TFE
%

Helicity

θ222/θ208

%
Helicity

15

cyclo-6,10(Ac-VSKLR[EQLVK]RKQN-NH )

0.61

55.9

0.79

75.7

21

cyclo-6,10(Ac-VSKLA[EQLVK]RAQN-NH )

0.84

88.0

0.84

87.9

22

cyclo-6,10(Ac-VSKLA[EQLVK]AKQN-NH )

0.82

80.9

0.84

86.5

23

cyclo-6,10(Ac-VSALR[EQLVK]RAQN-NH )

0.60

58.1

0.82

81.0

24

cyclo-6,10(Ac-VSALR[EQLVK]AKQN-NH )

0.72

69.8

0.83

84.3

2

2

2

2

2

The CD spectra and resulting percentage helicity of the alanine scan peptides showed
that three of the four peptides had increased α-helical character (21, 22, and 24) (Figure 3.4).
It was hypothesized that the same degree of helicity would be introduced in each sequence,
as the same two helix-stabilizing residues were introduced in all cases. However, when a
basic residue immediately preceding or following the staple is replaced with an alanine there
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is an increase in helicity, suggesting that the charged side chain of these basic residues may
have had a negative impact on the helicity of the sequences. This indicates that the placement
of basic residues is important in determining the optimal helicity, as compound 23 has the
basic residues surrounding the staple within the sequence and it contains the least amount of

Mean Residue Ellipticity (deg cm2/dmol)

helicity.
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Figure 3.4 - CD spectra from the lead cyclic peptide from HABD2 (15) compared with
the alanine scan sequences (21-24).

Of the alanine scan compounds, compound 21 has the greatest increase in helicity
compared to compound 15, and has a 4-fold increase in helicity compared to the linear
sequence of HABD2 (compound 12).
The alanine scan peptides were next analyzed by SPR to identify the peptides’
binding to HA compared to the lead sequence (15). These peptides were passed over the 5-10
kDa HA-coated chip at various concentrations as previously described in order to determine
their binding kinetics; the absorbance readings of each peptide were also plotted together to
compare their signals intensities at identical concentrations (Figure 3.5).
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Figure 3.5 - SPR binding curves for the lead cyclic peptide from HABD2 (15) and the
alanine scan sequences (21-24) that were passed over HA-coated gold chip at a
concentration of 25 µM.

Compound 15 still had the greatest signal intensity and the strongest binding affinity
(1.01 µM) towards HA, but peptide 23 showed comparable binding to HA with a KD of 3.08
µM. Compound 21, which had the greatest increase in helicity, actually had diminished
binding, with a KD that was higher than the linear sequence (Table 3.4). The other sequences
that had improved helicity (22 and 24), had worse binding compared to that of 15 and 23.
Site-directed mutagenesis of the HABDs of RHAMM discovered that the removal of the
basic residue at the beginning of HABD2 (K3 in the cyclic peptides mimicking HABD2) was
critical for binding of the RHAMM protein to HA6. Compounds 23 and 24 have this K3
residue replaced with an alanine, but have greater affinity to HA compared to 21 and 22
(where K3 is present). This highlights one of the differences between the properties of these
cyclic peptides mimicking RHAMM and the full-length protein.
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Table 3.4 - The calculated KD values determined by SPR for the alanine scan sequences
Cmpd

KD (µM)

21

4058

22

11

23

3.0

24

8.5

Compound 21 has the proper BX7B binding motif that was previously hypothesized
to be essential for binding to HA. However, these results show compound 21 has worse
binding to HA when compared to the other alanine sequences (22-24), and yet these
sequences do not have the exact BX7B motif. The diminished binding of compound 21
despite the large increase in helicity may be due to the positioning of the remaining basic
residues in the sequence when folded. This can be determined using a helical-wheel
projection, which shows the position of the amino acids in a sequence assuming that this
sequence allows for the formation of a perfect helix11. Helical wheel projections can be used
to gain an approximate understanding of where these basic residues fall in relation to the
staple; as these sequences do not form a perfect α-helix, the reported positions are
understood not to be the exact locations of the residues (Figure 3.6).
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Figure 3.6 - Helical wheel projection of the best cyclized sequence of HABD2 (15) and
the sequences resulting from the alanine scan of the basic residues (21-24). The basic
residues are highlighted in green and the alanine residues are in red.

When the Lys-12 and Arg-5 are both replaced by an alanine residue (as in compound
21), only Arg-11 and Lys-3 remain available for binding. These two residues are close to the
lactam bridge and are separated by Asn-14 and Gln-7. Asn and Gln both have long side
chains that could interfere with the binding of Lys/Arg to HA. All other sequences have
improved binding to HA when compared to 21, and this might be due to the presence of a
basic residue on the opposite face of the helix to the staple. The placement of residues away
from the staple appears to be imperative for binding, as compound 21 shows that a lack of
residues placed opposite to the staple results in a loss of binding. Compound 23 is seen to
have comparable binding to that of the best cyclic sequence (15), and this might be because
of an optimal spacing in the helical wheel of the basic residues. In addition, the amino acids
separating the basic residues in 23 (Leu and Val) have short, nonpolar side chains, which are
less likely to interact with HA than amino acids that have longer, polar side chains.
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3.3 Conclusions
As the cyclized peptide with the best binding to HA, compound 15 remains the lead
sequence across both HABD1 and HABD2 of RHAMM. The cyclic peptide derived from the
H. sapiens RHAMM sequence had improved helicity over the original M. musculus sequence
but did not bind HA as strongly. The replacement of two basic residues with alanine residues
also did not result in the positive correlation between helicity and binding to HA that was
previously seen in the HABD2 staple scan. In these instances, the specific residue replaced
by alanine appeared to be of importance: the placement of the positive residues on the
opposite face of the helix than to staple was required in order to bind HA. This was modeled
by the helical-wheel projection, which demonstrated that the placement of the staple close to
the two remaining basic residues within the sequence resulted in loss of binding.
It can also be seen that the there is not a need for the specific BX7B binding motif for
cyclic peptides that mimic HABD2. Compound 21, the only alanine scan sequence that has
the BX7B motif, was not able to bind to HA (KD = 4058 µM), while compound 23, that has a
BX5B motif, had comparable binding to HA as the lead cyclic peptide (15) (KD = 3.0 µM for
23; KD = 1.0 µM for 15). It can be concluded that the positioning of the positive residues in
three-dimensional space within these cyclic peptide sequences is the most important
determinant for binding. This allows for a better understanding of how these cyclic peptides
differ from that of the full protein sequence of RHAMM. This information on interactions
between ligands and cyclic peptide mimics can assist in the design of more peptide
therapeutics that inhibits protein-carbohydrate interactions.

3.4 Experimental
3.4.1

General information

All Fmoc-protected amino acids were obtained from ChemImpex. HCTU, HATU, and Rink
Amide

MBHA

Resin

(4-(2’,4’-dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-

aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl benzhydrylamine resin) were obtained
from ChemImpex. Tetrakis(triphenylphosphine)palladium(0), phenylsilane, Fmoc-AEEA
spacer, and NHS-Biotin were obtained from Sigma-Aldrich. All solvents were obtained from
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Fischer Thermo-Scientific.

3.4.2

Solid-phase peptide synthesis

Fmoc-based solid-phase synthesis was carried out by either manual synthesis using a fritted
glass peptide vessel or by automated synthesis using a Biotage® Syro Wave™ automated
peptide synthesizer. Synthesis was performed on a 0.1 mmol scale with 0.52 mmol/g FmocRink amide MBHA resin and a 3-fold excess of the protected amino acids. The resin was
swelled in CH2Cl2 (2.0 mL, 15 minutes) then rinsed with DMF (1.0 mL, 1 min). Fmoc
deprotection was performed with a solution of 20% piperidine/DMF (1.5 mL) 5 minutes,
then washed with three times with DMF (2.0 mL, vortex 30 seconds) and then again for
15min with 20% piperidine/DMF (1.5 mL). The resin was further washed with DMF six
times (2.0 mL, vortex 30 seconds). A Kaiser test was performed after the Fmoc removal to
verify the presence of a free primary amino group. Fmoc-protected amino acid (0.3 mmol)
and HCTU (0.3 mmol) was dissolved in DMF (1.5 mL) and added to the resin. The mixture
was vortexed for 30 seconds and then DIPEA (0.6 mmol) was added to the mixture and
vortexed for 1 hour. The deprotection/amino acid coupling cycle was repeated until the
desired amino acid sequence was obtained. After the final amino acid was coupled, the resin
was washed with DMF (3x) and CH2Cl2 (3x) and then dried under vacuum and stored in the
freezer (-20 ᴼC). Removal of the N-terminal Fmoc protecting group was achieved using the
previously described deprotection procedure. Cleavage of the peptide from the resin and side
chain protecting groups was performed by adding a solution of 95% trifluoroacetic acid/2.5%
triisopropylsilane/2.5% water (3 mL) to the resin and vortexing for 4-5 hours. After filtration,
the peptide was precipitated with cold tert-butyl methyl ether (TBME) (20 mL) and collected
by centrifugation. The mother liquor was decanted, the pellet dissolved in water (20mL) and
lyophilized to obtain the crude fully deprotected peptide.

3.4.3

Deprotection of the allyloxycarbonyl (Alloc) and allylester (OAll)

protecting groups
Selective deprotection of the allyloxycarbonyl and the allylester protecting groups was
accomplished by adding CH2Cl2 (4.5 mL) to the resin-bound peptide and shaking gently for
10 minutes. After addition of phenylsilane (24 eq), the peptide vessel was flushed with
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nitrogen for 5 minutes. Tetrakis(triphenylphosphine) palladium (0) (0.1 eq) was then added
to the mixture and the peptide vessel was again flushed with nitrogen, and the reaction was
allowed to proceed for 10 minutes. The peptide-resin was washed with CH2Cl2 (4 x 30
seconds), followed by a series of washings with CH2Cl2, DMF, MeOH, DMF, and CH2Cl2
(30 seconds each).

3.4.4

Lactam bridge formation

After selective deprotection of alloc and allyl ester groups, HATU (3 eq) was dissolved in
DMF (1.5 mL), added to the resin and vortexed for 30 seconds. DIPEA (6 eq) was then
added and the reaction was vortexed for 2 hours. The resin was rinsed with DMF and CH2Cl2
(2.0 ml, 3 x 30 seconds each) to remove any residual reactants.

3.4.5

Purification by RP-HPLC/ESI-MS

Peptides were analyzed using a reverse-phase analytical HPLC column (Agilent Zorbax SBC18 column 4.6 x 150 mm, 3.5 µm). This system was equipped with a Waters 600E
Multisolvent Delivery System, Waters 600 controller, Waters inline degasser, and Waters
Masslynx software (version 4.1). Employed mobile phases were 0.1% TFA in Milli-Q water
(eluent A) and 0.1% TFA in acetonitrile (eluent B). The flow rate was set at 1.5 mLmin-1
with a gradient elution over a 12 minute gradient. The column eluent was monitored using a
Waters 2998 Photodiode array detector. Peptides were purified using a reversed-phase
preparative HPLC column (Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 µm) on the
same system described above. The detection method and eluents were the same as the
analytical system, with the flow rate was set at 20 mLmin-1. The collected fractions were then
lyophilized to a solid and analyzed by ESI-MS. Purity of final products was determined by an
Acquity UHPLC-MS (220 nm).

3.4.6

Circular dichroism (CD) spectroscopy

CD spectra were obtained on a Jasco J-810 spectropolarimeter and recorded in the range of
180-260 nm. Peptide solutions were prepared with a 0.1 M phosphate buffer solution to a
concentration of 0.5 mM. The measurements were performed in quartz cuvettes with a path
length of 1 mm and a scanning speed of 10-50 nm/min. Five individual data points were
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averaged by the instrument in order to obtain the reported CD spectrum. The measurements
were carried out at 20 ᴼC. A blank solution of 0.1 M phosphate buffer solution was run
before every measurement in order to baseline correct for any UV-interference observed
from the buffer. Deconvolution of CD spectra were obtained using the CONTINLL program,
which is part of the web-based program CdPro (http://lamar.colostate.edu/~sreeram/CDPro/).

3.4.7

Surface plasmon resonance

HA was modified using a literature procedure, with some modifications12. 5-10kDa HA (40
mg) was dissolved in DMSO/H2O (7/3, v/v) with an excess amount of sodium
cyanoborohydride added. This solution was allowed to stir for 12 hours at room temperature,
10 eq of cystamine was added and the mixture was allowed to stir for a further 24 hours. The
solution was then added to a dialysis membrane (MWCO 3.5-5 kDa) where the by-products
were removed by dialysis for 3 days followed by lyophilization until a white powder was
obtained. SPR experiments were performed with an openSPR (Nicoya Lifesciences,
Waterloo, Canada) at 25°C with a 100 µL loading loop and a constant flow rate of 50
µL/min. The cystamine-modified HA was added to a functionalized gold chip by dissolving
HA-cystamine (1 mg/mL) in water and incubating for 24 hours at 4°C. Binding of the HABD
mimics and the linear sequences were tested in a 10mM solution of phosphate buffered saline
(137 mM NaCl, 2.7 mM KCl, 10mM Na2HPO4, 2 mM KH2PO4). The peptides were injected
over the bound HA in concentrations from 1 µM to 1 mM for 2 min to allow association. 10
mM PBS was passed over the sensor for 8 min to allow dissociation. After each peptide
injection, 1 mM NaCl was injected to completely dissociate the complex and regenerate the
HA surface. Data analysis was performed using Trace Drawer software (Ridgeview
Instruments AB) as recommended by the manufacturer. Kinetic parameters were calculated
using global analysis, fitting the data to a simple 1:1 model.
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Chapter 4

4

Conclusions

4.1 Outlooks and Conclusions
An elevated level of the receptor for hyaluronan mediated motility (RHAMM) has
been observed in malignant prostate cancer and is correlated with poor prognosis due to
increased likelihood of metastases1. RHAMM can bind to hyaluronan (HA) to promote cell
migration, inflammation, and fibrosis2. This interaction primarily occurs ionically between
the basic residues present in the two hyaluronan binding domains (HABDs) of RHAMM and
the carboxylic acids contained in HA3,4. The ability of the basic residues of RHAMM to bind
to HA is facilitated by the highly α-helical secondary structure of the protein. To make a
more drug-like molecule capable of interfering with RHAMM-HA interactions, truncating
the RHAMM sequence to contain only one of the binding domains is more favorable. A
truncated peptide would be a more drug-like molecule than the full-length protein, provided
that it still maintained affinity for the polysaccharide HA. Also, there is an advantage for a
shorter amino acid sequence than a large protein, due to ease of synthesis and lower
production costs. However, when the sequence is truncated, the elimination of stabilizing
residues causes loss of secondary structure; this would decrease interaction between the
peptide and HA. To maintain the secondary structure of this shortened sequence, cyclization
via stapling of two amino acid residues can be accomplished. This allows the peptide to
overcome the high energetic barrier that is associated with α-helix formation5. In this thesis,
both HABDs of the protein RHAMM were examined to determine whether a lactam bridgecyclized peptide could mimic the native interactions of RHAMM towards its endogenous
ligand HA.
A staple scan of both HABDs was performed to identify the cyclized sequence that
had the best induced helicity and binding to HA. When helicity was examined, the linear
sequences of the HABDs were tested in both water and a 40% trifluoroethanol (TFE)/water
solution. TFE can act to stabilize secondary structure; therefore the measured helicity of the
linear sequence in this solution can be viewed as the theoretical maximum helicity of the
sequence. Because these sequences are truncated and do not have the support of stabilizing
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residues in the native sequence, it is unlikely they will possess the same degree of helicity as
the full protein sequence.
When examining the helicity of the peptides containing HABD1, none of the staples
that were introduced achieved the same degree of helicity as the linear sequence in the 40%
TFE solution. However, when the staples were introduced to HABD2, there were two
sequences that acquired comparable helicity to that of the theoretical maximum helicity. This
difference in the effect that the staples had on HABD2 compared to HABD1 could be due to
the increased amount of helix stabilizing residues present in the HABD2 sequence.
The ability of all peptides to bind HA was also examined. The linear sequence of
HABD1 had greater binding to HA compared to the linear sequence of HABD2. This is
opposite of that was seen with the helicity, as HABD1 had a lower helical content than that
of HABD2. The introduction of staples to HABD1 increased HA binding in three out of the
five sequences tested, while the introduction of staples to HABD2 increased binding for all
four sequences tested. The lack of improved binding in two of the HABD1 sequences might
be due to the replacement of amino acids essential for binding in order to create the lactam
bridge; whereas in HABD2, no such residues were removed.
Through these staple scans, one lead peptide (15) produced a significant improvement
in helicity and binding to HA. This compound was cyclized between the amino acid residues
in position 6 and 10 of HABD2. This cyclized peptide was observed to inhibit migration of
cancer cells as well as the release of markers for inflammation and fibrosis. Peptide 15 also
had increased stability towards degradation via both trypsin and human serum. Modification
of this sequence to mimic the H. sapiens sequence was not possible; while the humanized
sequence increased helicity, it diminished binding to HA. Results of an alanine scan showed
that at least one basic residue must be on the opposite face of the helix relative to the staple
location (Figure 4.1). This may be due to the staple blocking the basic residues when on the
same face of the helix.
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Figure 4.1 - Helical wheel projection of lead cyclic peptide (15). At least one basic
residue must be present on the face of the helix that is opposite to the staple for binding
to HA.

To create a better drug candidate, this lead cyclized sequence can be further modified
to increase helicity while hopefully also improving binding to HA. While there was a
positive correlation between helicity and binding to HA present in the HABD2 staple scan,
this is not always the case. To further modify this sequence, helix-stabilizing residues could
be introduced between the stapling residues as a means of avoiding potential interference
with these amino acid side chains with binding to HA.
It is important to further evaluate the structure of this lead cyclized peptide. The
secondary structure could be more accurately resolved through the use of crystallography and
2D NMR spectroscopy studies. This would clarify which segments of the sequence contain
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an α-helical conformation, as the CD spectral data suggests a combination of secondary
structural elements.
Compound 15 has therapeutic potential in the treatment of cancer, such as prostate or
breast. Due to its ability to mimic RHAMM, compound 15 can bind to HA and block the
native interaction between RHAMM and HA. This can decrease cell migration and the
inflammation associated with cancer. Preventing the spread of a primary tumor through
decreased cell migration would help to decrease the formation of metastatic tumors, a major
cause of complications in cancer treatment6. Due to this and many other problems associated
with treating metastases, it would be beneficial to stop the parental tumor from spreading. If
a RHAMM-overexpressing tumor could be detected and diagnosed at an early stage, then a
peptide such as compound 15 could be added to a patient’s treatment regimen to prevent
metastasis or to slow the tumor’s ability to metastasize. This would be a novel therapeutic
route for cancer treatment.
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5

Appendix

5.1 Characterization of synthesized peptides
Table 1 – Sequences of HABD1 where (i, i+4) staples were placed in cyclized versions. All
sequences were amidated on the C-terminus and acetylated on the N-terminus.
ESI-MS
Cmpd

Sequence
Expected

Observed

[M+2H]2+ = 931.75

[M+2H]2+= 931.60

[M+3H]3+ = 621.33

[M+3H]3+= 621.32

1

Ac-NLKQKIKHVVKLKDE-NH2

2

cyclo-4,8(AcNLK[EKIKK]VVKLKDE-NH2)

[M+2H]2+= 918.07

[M+2H]2+= 918.77

[M+3H]3+= 612.38

[M+3H]3+= 612.81

3

cyclo-5,9(AcNLKQ[EIKHK]VKLKDE-NH2)

[M+2H]2+= 937.04

[M+2H]2+= 937.79

[M+3H]3+= 635.03

[M+3H]3+= 635.45

4

cyclo-6,10(AcNLKQK[EKHVK]KLKDE-NH2)

[M+2H]2+= 944.55

[M+2H]2+= 945.30

[M+3H]3+= 630.03

[M+3H]3+= 630.50

5

cyclo-7,11(AcNLKQKI[EHVVK]LKDE-NH2)

[M+2H]2+= 922.53

[M+2H]2+= 923.36

[M+3H]3+= 615.35

[M+3H]3+= 615.74

6

cyclo-8,12(AcNLKQKIK[EVVKK]KDE-NH2)

[M+2H]2+= 925.56

[M+2H]2+= 926.15

[M+3H]3+= 617.37

[M+3H]3+= 617.73

*Purity is determined by integrating the area under the LC curve

Purity
(%)*

>98

96.1

>98

>98

>98

97.2

2

Table 2 – Sequences of HABD2 where (i, i+4) staples were placed in cyclized versions. All
sequences were amidated on the C-terminus and either non-acetylated or acetylated the Nterminus.
ESI-MS
Cmpd

Sequence
Expected

Observed

[M+2H]2+ = 842.51

[M+2H]2+= 842.85

[M+3H]3+ = 562.01

[M+3H]3+= 562.31

[M+2H]2+= 848.99

[M+2H]2+= 848.80

[M+3H]3+= 566.33

[M+3H]3+= 566.13

[M+3H]3+= 556.33

[M+3H]3+= 556.36

[M+4H]4+= 417.49

[M+4H]4+= 417.52

7

H-VSKLRSQLVKRKQN-NH2

8

cyclo-4,8(H-VSK[ERSQK]VKRKQNNH2)

9

cyclo-5,9(H-VSKL[ESQLK]KRKQN-NH2)

10

cyclo-6,10(H-VSKLR[EQLVK]RKQNNH2)

[M+2H]2+= 854.02

[M+2H]2+= 854.45

[M+3H]3+= 569.68

[M+3H]3+= 569.85

11

cyclo-7,11(H-VSKLRS[ELVKK]KQNNH2)

[M+2H]2+= 819.50

[M+2H]2+= 819.93

[M+3H]3+= 546.67

[M+3H]3+= 546.63

12

Ac-VSKLRSQLVKRKQN-NH2

[M+2H]2+ =863.75

[M+2H]2+ = 863.50

[M+3H]3+ = 575.92

[M+3H]3+ = 575.92

13

cyclo-4,8(Ac-VSK[ERSQK]VKRKQNNH2)

[M+2H]2+ =869.89

[M+2H]2+ = 870.28

[M+3H]3+ = 580.33

[M+3H]3+ = 580.25

14

cyclo-5,9(Ac-VSKL[ESQLK]KRKQNNH2)

[M+2H]2+ =855.43

[M+2H]2+ = 855.45

[M+3H]3+ = 570.62

[M+3H]3+ = 570.59

15

cyclo-6,10(Ac-VSKLR[EQLVK]RKQNNH2)

[M+2H]2+ =876.10

[M+2H]2+ = 876.24

[M+3H]3+ = 583.91

[M+3H]3+ = 583.56

16

cyclo-7,11(Ac-VSKLRS[ELVKK]KQNNH2)

[M+2H]2+ = 840.51

[M+2H]2+ = 840.88

[M+3H]3+ = 560.67

[M+3H]3+ = 560.81

17

cyclo-5,9(Ac-VSKL[KSQLE]KRKQNNH2)

[M+2H]2+ =855.43

[M+2H]2+ = 855.51

[M+3H]3+ = 570.62

[M+3H]3+ = 570.72

18

cyclo-6,10(Ac-VSKLR[KQLVE]RKQNNH2)

[M+2H]2+ =876.10

[M+2H]2+ = 876.11

[M+3H]3+ = 583.91

[M+3H]3+ = 584.49

Purity
(%)

>98

>98

97.5

>98

>98

>98

>98

>98

96.3

>98

>98

>98

3

Table 3 – Sequences of HABD2 derived from Homo sapiens where (i, i+4) staples were
placed in cyclized versions. All sequences were amidated on the C-terminus and acetylated
on the N-terminus.
ESI-MS
Cmpd

Sequence

19

Ac-VSKLRCQLLAKKKQS-NH2

20

cyclo-6,10(AcVSKLR[EQLAK]KKQS-NH2)

Expected

Observed

[M+2H]2+ = 822.03

[M+2H]2+= 822.33

[M+3H]3+ = 548.02

[M+3H]3+= 548.67

[M+2H]2+ = 833.5

[M+2H]2+= 834.35

[M+3H]3+ = 556.00

[M+3H]3+= 556.64

Purity
(%)

>98

>98

Table 4 – Sequences of the alanine scan of HABD2 where (i, i+4) staples were placed in
cyclized versions. All sequences were amidated on the C-terminus and acetylated on the Nterminus.
ESI-MS
Cmpd

Sequence

21

cyclo-6,10(Ac-VSKLA[EQLVK]RAQN-NH )

22

cyclo-6,10(Ac-VSKLA[EQLVK]AKQN-NH )

23

cyclo-6,10(Ac-VSALR[EQLVK]RAQN-NH )

24

cyclo-6,10(Ac-VSALR[EQLVK]AKQN-NH )

2

2

2

2

Expected

Observed

[M+2H]2+ = 812.97

[M+2H]2+= 812.86

[M+3H]3+ = 542.31

[M+3H]3+= 542.78

[M+2H]2+ = 803.96

[M+2H]2+= 804.96

[M+3H]3+ = 536.31

[M+3H]3+= 537.01

[M+2H]2+ = 817.97

[M+2H]2+= 818.62

[M+3H]3+ = 545.64

[M+3H]3+= 546.31

[M+2H]2+ = 803.96

[M+2H]2+= 804.85

[M+3H]3+ = 536.31

[M+3H]3+= 536.99

Purity
(%)

>98

>98

>98

>98
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5.2

Trypsin degradation products

5.2.1

Trypsin Degradation Products of Compound 12

5

5.2.2

Trypsin Degradation Products of Compound 15

6

5.3

HPLC Traces

AU

Compound 1
2.0E+07
1.8E+07
1.6E+07
1.4E+07
1.2E+07
9.5E+06
7.5E+06
5.5E+06
3.5E+06
1.5E+06
-5.0E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%

[M+2H]2+

m/z

9

11

13

15

7

Compound 2
7.5E+06
6.5E+06
5.5E+06

AU

4.5E+06
3.5E+06
2.5E+06
1.5E+06
5.0E+05
-5.0E+05
0

2

4

6

8
Time (min)

[M+3H]3+

%
[M+2H]2+

m/z

10

12

14

8

AU

Compound 3
4.9E+06
4.4E+06
3.9E+06
3.4E+06
2.9E+06
2.4E+06
1.9E+06
1.4E+06
9.0E+05
4.0E+05
-1.0E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%

[M+2H]2+

m/z

9

11

13

15

9

Compound 4
8.7E+06
7.7E+06
6.7E+06

AU

5.7E+06
4.7E+06
3.7E+06
2.7E+06
1.7E+06
6.5E+05
-3.5E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%

[M+2H]2+

m/z

9

11

13

15

10

Compound 5
1.8E+07
1.6E+07
1.4E+07

AU

1.2E+07
9.7E+06
7.7E+06
5.7E+06
3.7E+06
1.7E+06
-3.5E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%
[M+2H]2+

m/z

9

11

13

15

11

Compound 6
5.8E+06
4.8E+06

AU

3.8E+06
2.8E+06
1.8E+06
7.5E+05
-2.5E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%

[M+2H]2+

m/z

9

11

13

15

12

Compound 7
7.0E+05
6.0E+05
5.0E+05

AU

4.0E+05
3.0E+05
2.0E+05
1.0E+05
0.0E+00
-1.0E+05
-2.0E+05
0

2

4

6

[M+3H]3+

%
[M+2H]2+

m/z

8
Time (min)

10

12

14

13

Compound 8
1.4E+06
1.2E+06
1.0E+06
AU

8.0E+05
6.0E+05
4.0E+05
2.0E+05
0.0E+00
-2.0E+05
0

2

4

6
Time (min)

[M+3H]3+

%
[M+2H]2+

m/z

8

10

12

14

Compound 9
6.0E+05
5.0E+05
4.0E+05
3.0E+05
AU

2.0E+05
1.0E+05
0.0E+00
-1.0E+05
-2.0E+05
-3.0E+05
-4.0E+05
0

2

4

6
Time (min)

[M+4H]4+

[M+3H]3+
%

[M+2H]2+

m/z

8

10

12

15

Compound 10
1.5E+07
1.3E+07
1.1E+07

AU

9.0E+06
7.0E+06
5.0E+06
3.0E+06
1.0E+06
-1.0E+06 0

2

4

6
Time (min)

[M+3H]3+

%
[M+2H]2+

m/z

8

10

12

16

Compound 11
7.0E+06
6.0E+06
5.0E+06

AU

4.0E+06
3.0E+06
2.0E+06
1.0E+06
0.0E+00
-1.0E+06

0

2

4

6
Time (min)

[M+3H]3+

[M+2H]2+
%

m/z

8

10

12

17

Compound 12
3.9E+07
3.4E+07
2.9E+07
AU

2.4E+07
1.9E+07
1.4E+07
9.0E+06
4.0E+06
-1.0E+06

0

2

4

6
Time (min)

[M+3H]3+

%

[M+2H]2+

m/z

8

10

12

18

Compound 13
1.4E+06
1.2E+06
1.0E+06

AU

8.0E+05
6.0E+05
4.0E+05
2.0E+05
0.0E+00
-2.0E+05
-4.0E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%

[M+2H]2+

m/z

9

11

13

15

19

Compound 14
1.9E+06
1.7E+06
1.5E+06
1.3E+06
AU

1.1E+06
9.0E+05
7.0E+05
5.0E+05
3.0E+05
1.0E+05
-1.0E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%
[M+2H]2+

m/z

9

11

13

15

20

Compound 15
1.6E+07
1.4E+07
1.2E+07
AU

9.5E+06
7.5E+06
5.5E+06
3.5E+06
1.5E+06
-5.0E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%
[M+2H]2+

m/z

9

11

13

15

21

Compound 16
1.6E+07
1.4E+07
1.2E+07
AU

9.5E+06
7.5E+06
5.5E+06
3.5E+06
1.5E+06
-5.0E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%
[M+2H]2+

m/z

9

11

13

15

22

Compound 17
3.9E+06
3.4E+06
2.9E+06
AU

2.4E+06
1.9E+06
1.4E+06
8.5E+05
3.5E+05
-1.5E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%

[M+2H]2+

m/z

9

11

13

15

23

Compound 18
5.9E+06
4.9E+06

AU

3.9E+06
2.9E+06
1.9E+06
8.5E+05
-1.5E+05
-1

1

3

5

7
Time (min)

[M+3H]3+

%
[M+2H]2+

m/z

9

11

13

15

24

Compound 19
4.20E+06
3.70E+06
3.20E+06
2.70E+06
AU

2.20E+06
1.70E+06
1.20E+06
7.00E+05
2.00E+05
-3.00E+05
0

2

4

6
Time (min)

[M+3H]3+

[M+2H]2+
%

m/z

8

10

12

25

Compound 20
2.70E+06
2.20E+06
1.70E+06
AU

1.20E+06
7.00E+05
2.00E+05

-3.00E+05
0

2

4

6
Time (min)

[M+3H]3+

[M+2H]2+
%

m/z

8

10

12

26

Compound 21
2.20E+06
1.70E+06

AU

1.20E+06
7.00E+05
2.00E+05
-3.00E+05
0

2

4

6
Time (min)

[M+3H]3+

%

[M+2H]2+

m/z

8

10

12

27

Compound 22
1.16E+07
9.60E+06
7.60E+06
AU

5.60E+06
3.60E+06
1.60E+06

-4.00E+05
0

2

4

6
Time (min)

[M+2H]2+

%

[M+3H]3+

m/z

m/z

8

10

12

28

Compound 23
1.16E+07
9.60E+06
7.60E+06
AU

5.60E+06
3.60E+06
1.60E+06

-4.00E+05
0

2

4

6
Time (min)

[M+2H]2+
[M+3H]3+

%

m/z

8

10

12

29

Compound 24
1.56E+07
1.36E+07
1.16E+07
9.60E+06
AU

7.60E+06
5.60E+06
3.60E+06
1.60E+06

-4.00E+05
0

2

4

6
Time (min)

[M+3H]3+
[M+2H]2+

%

m/z

8

10

12

30
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